drugset / Trial / NCT00496756
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
Phase 2
Terminated
14 enrolled
University of Nebraska
Bayer · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying the side effects and how well sorafenib works in treating patients with metastatic or unresectable kidney cancer.
Timeline
- Start
- 2007-03-01
- Primary completion
- 2009-10-31
- Completion
- 2014-04-25
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual rate”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 800 mg | Oral |